FDA Approves Avacopan for Rare ANCA Autoimmune Disease FDA Approves Avacopan for Rare ANCA Autoimmune Disease

ChemoCentryx said it plans to price its new medicine at an annual cost of $150,000 to $200,000 for US patients.Orphan Drug Approvals
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Rheumatology News Alert Source Type: news